Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells
Department of Medicine, Division of Infectious Disease & Immunology
Immunity | Immunology and Infectious Disease | Immunology of Infectious Disease | Infectious Disease | Virology
We previously reported that rOv-ASP-1, a recombinant Onchocerca volvulus activation associated protein-1, was a potent adjuvant for recombinant protein or synthetic peptide-based Ags. In this study, we further evaluated the adjuvanticity of rOv-ASP-1 and explored its mechanism of action. Consistently, recombinant full-length spike protein of SARS-CoV or its receptor-binding domain in the presence of rOv-ASP-1 could effectively induce a mixed but Th1-skewed immune response in immunized mice. It appears that rOv-ASP-1 primarily bound to the APCs among human PBMCs and triggered Th1-biased proinflammatory cytokine production probably via the activation of monocyte-derived dendritic cells and the TLR, TLR2, and TLR4, thus suggesting that rOv-ASP-1 is a novel potent innate adjuvant.
DOI of Published Version
J Immunol. 2009 Apr 1;182(7):4005-16. doi: 10.4049/jimmunol.0800531. Link to article on publisher's site
Journal of immunology (Baltimore, Md. : 1950)
He Y, Golenbock DT, Lustigman S. (2009). Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells. Infectious Diseases and Immunology Publications. https://doi.org/10.4049/jimmunol.0800531. Retrieved from https://escholarship.umassmed.edu/infdis_pp/397